Menu

DNA Methylation: Timekeeper of Biological Age

Join us to learn more about the role of epigenetic modifications in biological age and the aging process.

Jun 1, 2018
The Scientist Creative Services Team

DNA Methylation: Timekeeper of Biological Age from thescientistllc on Vimeo.

Cellular senescence, telomere shortening, and changes in gene expression have been well documented to contribute to the aging process. Recently, researchers have found that epigenetic changes, such as the presence of methyl groups in close proximity to CpG dinucleotides located near a gene’s promoter, correlate with age. Technological advances, including microarray analysis and next-generation sequencing, have clarified the relationship between DNA methylation and aging, to the point that such phenomena may even be used to predict one’s chronological age. For a detailed look at the biology of human aging and the dynamics of DNA methylation, The Scientist is bringing together a panel of experts to share their research, to discuss how the epigenome influences aging, and to highlight the approaches scientists are taking to study the possibility of targeting epigenetic modifications for therapeutic intervention. Attendees will learn how the epigenome controls aging from renowned experts in our interactive setting.

Topics to be covered:

  • The role of persistent and ephemeral epigenetic marks in setting and resetting cellular age
  • Targeting the disease of aging with pharmaceuticals

Meet the Speakers:

Steve Horvath, PhD, ScD
Professor, Department of Human Genetics and Biostatistics
University of California, Los Angeles

 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.